Journal
JOURNAL OF CARDIOVASCULAR TRANSLATIONAL RESEARCH
Volume 8, Issue 8, Pages 458-465Publisher
SPRINGER
DOI: 10.1007/s12265-015-9655-z
Keywords
Scavenger receptor; LOX-1; Oxidized LDL; Atherosclerosis; Biomarker
Funding
- Leeds Teaching Hospitals National Health Service Trust
- Brunei government
- British Heart Foundation [PG/09/054/27838] Funding Source: researchfish
Ask authors/readers for more resources
Lectin-like oxidized low-density lipoprotein receptor-1 (SR-E1, LOX-1, OLR1) was first discovered as a vascular receptor for modified lipoprotein particles nearly 20 years ago. Since then, in vitro and in vivo studies have demonstrated an association between LOX-1, a soluble form (sLOX-1) and a number of diseases including atherosclerosis, arthritis, hypertension and pre-eclampsia. However, converting such discoveries into tools and drugs for routine clinical use is dependent on translational preclinical and clinical studies but such studies have only begun to emerge in the past decade. In this review, we identify the key clinical applications and corresponding criteria that need to be addressed for the effective use of LOX-1-related probes and molecules for patient benefit in different disease states.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available